$CVKD
Cadrenal Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023084937 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $902.1K
YoY Change -60.91%
% of Gross Profit
Research & Development $361.1K $243.9K $56.39K
YoY Change -8.08% 332.62%
% of Gross Profit
Depreciation & Amortization $1.980K $597.00 $506.00
YoY Change 55.91% 17.98%
% of Gross Profit
Operating Expenses $1.264M $1.143M $972.8K
YoY Change -53.22% 17.46%
Operating Profit -$1.143M -$972.8K
YoY Change 17.46%
Interest Expense $119.8K $13.54K
YoY Change -102.98%
% of Operating Profit
Other Income/Expense, Net $106.1K -$53.32K
YoY Change -299.06%
Pretax Income -$1.144M
YoY Change -82.96%
Income Tax
% Of Pretax Income
Net Earnings -$1.144M -$1.036M -$1.026M
YoY Change -82.96% 1.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$0.13
Diluted Earnings Per Share -$1.07 -$0.07 -$0.13
COMMON SHARES
Basic Shares Outstanding 13.02M shares 13.02M shares 8.037M shares
Diluted Shares Outstanding 15.40M shares 8.037M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $8.403M
YoY Change 25682.45%
Cash & Equivalents $8.403M $9.109M $103.1K
Short-Term Investments
Other Short-Term Assets $89.67K
YoY Change -87.1%
Inventory
Prepaid Expenses $89.67K $168.6K
Receivables
Other Receivables
Total Short-Term Assets $8.492M $9.278M
YoY Change 1067.15%
LONG-TERM ASSETS
Property, Plant & Equipment $2.287K $2.884K
YoY Change 125.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.792K $3.792K
YoY Change -36.66%
Total Long-Term Assets $27.08K $33.57K
YoY Change -46.46%
TOTAL ASSETS
Total Short-Term Assets $8.492M $9.278M
Total Long-Term Assets $27.08K $33.57K
Total Assets $8.519M $9.312M
YoY Change 994.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $167.3K $141.7K
YoY Change -58.68%
Accrued Expenses $638.2K $396.9K
YoY Change -26.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $826.9K $563.6K
YoY Change -38.04%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $826.9K $563.6K
Total Long-Term Liabilities $0.00
Total Liabilities $826.9K $565.8K
YoY Change -86.94%
SHAREHOLDERS EQUITY
Retained Earnings -$15.07M -$13.93M
YoY Change 124.47%
Common Stock $22.76M $13.02K
YoY Change 277710.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.692M $8.746M -$1.180M
YoY Change
Total Liabilities & Shareholders Equity $8.519M $9.312M
YoY Change 994.77%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$1.144M -$1.036M -$1.026M
YoY Change -82.96% 1.01%
Depreciation, Depletion And Amortization $1.980K $597.00 $506.00
YoY Change 55.91% 17.98%
Cash From Operating Activities -$3.530M
YoY Change 398.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$3.250K
YoY Change 42.54%
Cash From Investing Activities -$3.250K
YoY Change 42.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 11.90M
YoY Change 1642.44%
NET CHANGE
Cash From Operating Activities -3.530M
Cash From Investing Activities -3.250K
Cash From Financing Activities 11.90M
Net Change In Cash 8.370M
YoY Change -31030.97%
FREE CASH FLOW
Cash From Operating Activities -$3.530M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
32082
dei City Area Code
CityAreaCode
(904)
dei Local Phone Number
LocalPhoneNumber
300-0701
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CVKD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41596
dei Entity Registrant Name
EntityRegistrantName
CADRENAL THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0860746
dei Entity Address Address Line1
EntityAddressAddressLine1
822 A1A North
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 306
dei Entity Address City Or Town
EntityAddressCityOrTown
Ponte Vedra
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13022754 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9109445 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32586 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
168602 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
22715 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
672295 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
9278047 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
727596 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2884 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1013 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26895 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43578 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3792 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5987 usd
CY2023Q3 us-gaap Assets
Assets
9311618 usd
CY2022Q4 us-gaap Assets
Assets
778174 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
141658 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
404897 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
396917 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
863564 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24991 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22288 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
43728 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
563566 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1334477 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
110380 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4379944 usd
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
40213 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2232 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21350 usd
CY2023Q3 us-gaap Liabilities
Liabilities
565798 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6329324 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13022754 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13022754 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8193875 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8193875 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
13022 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8194 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
22660153 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1154985 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13927355 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6714329 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8745820 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5551150 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9311618 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
778174 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
898051 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
915897 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2647407 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1348670 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
243948 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56388 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3720222 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
276482 usd
CY2023Q3 us-gaap Depreciation
Depreciation
597 usd
CY2022Q3 us-gaap Depreciation
Depreciation
506 usd
us-gaap Depreciation
Depreciation
1383 usd
us-gaap Depreciation
Depreciation
506 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1142596 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
972791 usd
us-gaap Operating Expenses
OperatingExpenses
6369012 usd
us-gaap Operating Expenses
OperatingExpenses
1625658 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1142596 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-972791 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6369012 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1625658 usd
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
106145 usd
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
3 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
129321 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
20 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
13544 usd
us-gaap Interest Expense
InterestExpense
3534 usd
us-gaap Interest Expense
InterestExpense
22088 usd
CY2022Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
18470 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
13567 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
29302 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
21312 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
216095 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
27874 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-740139 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
106145 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-53323 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-844014 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-79244 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1036451 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1026114 usd
us-gaap Net Income Loss
NetIncomeLoss
-7213026 usd
us-gaap Net Income Loss
NetIncomeLoss
-1704902 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15396224 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8037218 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12640815 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7778778 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3175922 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
98933 usd
CY2023Q3 cvkd Issuance Of Common Shares Prefunded Warrants And Warrants In Private Placement Net Of Fees
IssuanceOfCommonSharesPrefundedWarrantsAndWarrantsInPrivatePlacementNetOfFees
-6507416 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1036451 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8745820 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5551150 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
5408575 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1140700 usd
cvkd Derecognition Of Derivative Liabilities
DerecognitionOfDerivativeLiabilities
4596039 usd
cvkd Issuance Of Common Shares Prefunded Warrants And Warrants In Private Placement Net Of Fees
IssuanceOfCommonSharesPrefundedWarrantsAndWarrantsInPrivatePlacementNetOfFees
-6507416 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
250000 usd
us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
3000000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
108276 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
498990 usd
us-gaap Net Income Loss
NetIncomeLoss
-7213026 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8745820 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-670838 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
478684 usd
CY2022Q3 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
38445 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1026114 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1179823 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7950 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
478684 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
38445 usd
us-gaap Net Income Loss
NetIncomeLoss
-1704902 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1179823 usd
us-gaap Net Income Loss
NetIncomeLoss
-7213026 usd
us-gaap Net Income Loss
NetIncomeLoss
-1704902 usd
us-gaap Depreciation
Depreciation
1383 usd
us-gaap Depreciation
Depreciation
506 usd
us-gaap Share Based Compensation
ShareBasedCompensation
607266 usd
us-gaap Share Based Compensation
ShareBasedCompensation
478684 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
13567 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
29302 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
216095 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
27874 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-740139 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
268 usd
cvkd Issuance Of Shares To Settle Asset Purchase Agreement
IssuanceOfSharesToSettleAssetPurchaseAgreement
3000000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
145887 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
24033 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-672295 usd
us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
414240 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2196 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2195 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-263239 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
308221 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-466935 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
364141 usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-22088 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2835878 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-914554 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3254 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2278 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3254 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2278 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1011964 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7950 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6507416 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
250000 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
250000 usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
5408575 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11915991 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1019914 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
9076859 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
103082 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32586 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9109445 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103082 usd
us-gaap Stock Issued1
StockIssued1
1140700 usd
cvkd Derecognition Of Derivative Liabilities
DerecognitionOfDerivativeLiabilities
4596039 usd
cvkd Issuance Of Common Shares For Consulting Services
IssuanceOfCommonSharesForConsultingServices
108276 usd
us-gaap Net Income Loss
NetIncomeLoss
-7213026 usd
CY2023Q3 cvkd Non Cash Expenses
NonCashExpenses
4578450 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2835878 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9109445 usd
CY2023Q3 cvkd Workings Capital
WorkingsCapital
8714481 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-13927355 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of financial instruments, the fair value of common stock, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances change. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of Credit and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents. Cash is maintained at high credit quality financial institutions and, at times, balances may exceed federally insured limits. All interest-bearing and non-interest-bearing cash balances are insured up to $250,000 per depositor at each financial institution. The Company has never experienced any losses related to these balances. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is subject to a number of risks common for early-stage biopharmaceutical companies including, but not limited to, dependency on the clinical and commercial success of its product candidate, ability to obtain regulatory approval of its product candidate, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</p>
us-gaap Interest Income Deposit With Financial Institution Increase Decrease
InterestIncomeDepositWithFinancialInstitutionIncreaseDecrease
250000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Revenue Recognition Customer Acquisitions
RevenueRecognitionCustomerAcquisitions
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Acquisitions</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates acquisitions of assets and other similar transactions to assess whether or not the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine whether substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If so, the transaction is accounted for as an asset acquisition. If not, further determination is required as to whether or not the Company has acquired inputs and processes that have the ability to create outputs, which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acquisitions meeting the definition of business combinations are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. In a business combination, any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For asset acquisitions, a cost accumulation model is used to determine the cost of an asset acquisition. Direct transaction costs are recognized as part of the cost of an asset acquisition. The Company also evaluates which elements of a transaction should be accounted for as a part of an asset acquisition and which should be accounted for separately. The cost of an asset acquisition, including transaction costs, is allocated to identifiable assets acquired and liabilities assumed based on a relative fair value basis. Goodwill is not recognized in an asset acquisition. Any difference between the cost of an asset acquisition and the fair value of the net assets acquired is allocated to the non-monetary identifiable assets based on their relative fair values. When a transaction accounted for as an asset acquisition includes an in-process research and development (“IPR&amp;D”) asset, the IPR&amp;D asset is only capitalized if it has an alternative future use other than in a particular research and development project. For an IPR&amp;D asset to have an alternative future use: (a) the Company must reasonably expect that it will use the asset acquired in an alternative manner and anticipate economic benefit from that alternative use, and (b) the Company’s use of the asset acquired is not contingent on the further development of the asset subsequent to the acquisition date (that is, the asset can be used in an alternative manner in the condition in which it existed at the acquisition date). Otherwise, amounts allocated to IPR&amp;D that have no alternative use are expensed to research and development. Asset acquisitions may include contingent consideration arrangements that encompass obligations to make future payments to sellers contingent upon the achievement of future financial targets. Contingent consideration is not recognized until all contingencies are resolved and the consideration is paid or probable of payment, at which point the consideration is allocated to the assets acquired on a relative fair value basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i> </i></b></p>
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50 pure
CY2022Q4 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
4379944 usd
CY2022Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
4379944 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
474348 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
3905596 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
4379944 usd
CY2022Q4 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
4379944 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
216095 usd
CY2023Q3 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
4596039 usd
CY2023Q3 cvkd Accrued Consulting Fees
AccruedConsultingFees
3571 usd
CY2022Q4 cvkd Accrued Consulting Fees
AccruedConsultingFees
165192 usd
CY2023Q3 us-gaap Compensated Absences Liability
CompensatedAbsencesLiability
355528 usd
CY2022Q4 us-gaap Compensated Absences Liability
CompensatedAbsencesLiability
605290 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
37818 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
93082 usd
CY2023Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
396917 usd
CY2022Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
863564 usd
CY2022Q2 us-gaap Payments For Purchase Of Other Assets1
PaymentsForPurchaseOfOtherAssets1
100000 usd
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
100000 usd
us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
2000000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.35 pure
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
20095 usd
us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
200000 usd
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
20095 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
220095 usd
CY2023Q1 us-gaap Shares Issued
SharesIssued
600000 shares
CY2023Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3000000 usd
CY2023Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
60763 usd
CY2022Q4 cvkd Convertible Notes Payable Related Parties
ConvertibleNotesPayableRelatedParties
550000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
107040 usd
CY2022Q4 us-gaap Other Notes Payable
OtherNotesPayable
442960 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
575000 usd
CY2022Q4 cvkd Debt Issuance Costs1
DebtIssuanceCosts1
464620 usd
CY2022Q4 cvkd Convertible Debt1
ConvertibleDebt1
110380 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
250000 usd
CY2022Q4 cvkd Debt Issuance Costs2
DebtIssuanceCosts2
206272 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
43728 usd
CY2022Q4 us-gaap Debt Current
DebtCurrent
597068 usd
CY2023Q3 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
15000 shares
us-gaap Extinguishment Of Debt Gain Loss Per Share Net Of Tax
ExtinguishmentOfDebtGainLossPerShareNetOfTax
1
CY2022Q1 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
0.80 pure
CY2022Q2 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
0.60 pure
CY2023Q1 us-gaap Stock Dividends Shares
StockDividendsShares
1140700 shares
CY2023Q1 cvkd Warrant Exercise
WarrantExercise
250000 usd
CY2023Q1 cvkd Warrant Exercise Pay Off
WarrantExercisePayOff
250000 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
740139 usd
CY2023Q1 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
740139 usd
CY2022Q1 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
125000 shares
CY2022Q1 us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
7500 usd
CY2022Q4 us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
514792 shares
CY2022Q2 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
450000 shares
us-gaap Conversion Of Stock Shares Converted1
ConversionOfStockSharesConverted1
50000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1175000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y10M20D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
42000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.09
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
779594 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P1Y7M6D
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26895 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43578 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24991 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
22288 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2232 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21350 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27223 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
43638 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
6618 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
19892 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
3761 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
8650 usd
CY2023Q3 us-gaap Increase Decrease In Operating Liabilities
IncreaseDecreaseInOperatingLiabilities
6501 usd
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.12 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6566 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
22319 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28885 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1662 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
27223 usd
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
7500000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023Q1 cvkd Gross Proceeds
GrossProceeds
7000000 usd
CY2023Q1 us-gaap Credit Derivative Liquidation Proceeds Monetary Amount
CreditDerivativeLiquidationProceedsMonetaryAmount
5408575 usd
CY2023Q1 cvkd Purchase An Aggregate Shares
PurchaseAnAggregateShares
84000 shares
CY2023Q1 us-gaap Shares Acquired Weighted Average Discount To Net Assets Percentage
SharesAcquiredWeightedAverageDiscountToNetAssetsPercentage
0.06 pure
CY2023Q1 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
6
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
1.20 pure
CY2023Q3 cvkd Combined Purchase Price Of Warrant
CombinedPurchasePriceOfWarrant
1.7499
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
7500000 usd
us-gaap Sale Of Stock Percentage Of Ownership After Transaction
SaleOfStockPercentageOfOwnershipAfterTransaction
0.0999 pure
CY2023Q1 cvkd Stock Options Granted
StockOptionsGranted
50000 shares
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
435642 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
329420 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
435642 usd
CY2023Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
92309 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
276500 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
7634001 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
250000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
7660501 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2000000 shares
CY2023Q3 us-gaap Shares Issued
SharesIssued
685000 shares
cvkd Stock Options Granted Shares Term
stockOptionsGrantedSharesTerm
P10Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1100000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y6M25D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4578000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
75000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.2
cvkd Weighted Average Remaining Contractual Life Years Granted
WeightedAverageRemainingContractualLifeYearsGranted
P9Y9M21D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1175000 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M20D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
495834 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.64
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y9M21D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4216 usd
CY2022Q3 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
43042 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
277846 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
43042 usd
CY2023Q3 cvkd Employee Benefit And Share Based Compensation
EmployeeBenefitAndShareBasedCompensation
153072 usd
CY2022Q3 cvkd Employee Benefit And Share Based Compensation
EmployeeBenefitAndShareBasedCompensation
478684 usd
cvkd Employee Benefit And Share Based Compensation
EmployeeBenefitAndShareBasedCompensation
607266 usd
cvkd Employee Benefit And Share Based Compensation
EmployeeBenefitAndShareBasedCompensation
478684 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1036451 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1026114 usd
us-gaap Net Income Loss
NetIncomeLoss
-7213026 usd
us-gaap Net Income Loss
NetIncomeLoss
-1704902 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15396224 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8037218 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12640815 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7778778 shares
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8835501 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1061500 shares
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
usd
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12640815 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15396224 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7778778 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8037218 shares
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
usd
cvkd Issuance Of Shares To Settle Asset Purchase Agreement
IssuanceOfSharesToSettleAssetPurchaseAgreement
usd
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Proceeds From Other Equity
ProceedsFromOtherEquity
usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
us-gaap Stock Issued1
StockIssued1
usd
cvkd Derecognition Of Derivative Liabilities
DerecognitionOfDerivativeLiabilities
usd
cvkd Issuance Of Common Shares For Consulting Services
IssuanceOfCommonSharesForConsultingServices
usd
CY2023Q3 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
usd
CY2023Q3 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
usd
CY2022Q1 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
usd
CY2023Q3 us-gaap Deferred Tax Liabilities Derivatives
DeferredTaxLiabilitiesDerivatives
usd
CY2023Q3 cvkd Convertible Notes Payable Related Parties
ConvertibleNotesPayableRelatedParties
usd
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
usd
CY2023Q3 us-gaap Other Notes Payable
OtherNotesPayable
usd
CY2023Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
usd
CY2023Q3 cvkd Debt Issuance Costs1
DebtIssuanceCosts1
usd
CY2023Q3 cvkd Convertible Debt1
ConvertibleDebt1
usd
CY2023Q3 us-gaap Notes Payable
NotesPayable
usd
CY2023Q3 cvkd Debt Issuance Costs2
DebtIssuanceCosts2
usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q3 us-gaap Debt Current
DebtCurrent
usd
CY2023Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
cvkd Share Based Compensation Arrangement By Share Based Payment Award Options Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
cvkd Weighted Average Remaining Contractual Life Years Exercised
WeightedAverageRemainingContractualLifeYearsExercised
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
cvkd Weighted Average Remaining Contractual Life Years Canceled
WeightedAverageRemainingContractualLifeYearsCanceled
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12640815 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15396224 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7778778 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8037218 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001937993

Files In Submission

Name View Source Status
0001213900-23-084937-index-headers.html Edgar Link pending
0001213900-23-084937-index.html Edgar Link pending
0001213900-23-084937.txt Edgar Link pending
0001213900-23-084937-xbrl.zip Edgar Link pending
cvkd-20230930.xsd Edgar Link pending
f10q0923ex31-1_cadrenal.htm Edgar Link pending
f10q0923ex31-2_cadrenal.htm Edgar Link pending
f10q0923ex32-1_cadrenal.htm Edgar Link pending
f10q0923ex32-2_cadrenal.htm Edgar Link pending
f10q0923_cadrenal.htm Edgar Link pending
cvkd-20230930_def.xml Edgar Link unprocessable
cvkd-20230930_pre.xml Edgar Link unprocessable
cvkd-20230930_cal.xml Edgar Link unprocessable
cvkd-20230930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0923_cadrenal_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending